TheraRadar
Clinical-Stage Companies / QED Therapeutics, a BridgeBio company

QED Therapeutics, a BridgeBio company

Pre-Approval PRO BETA
9
Total Trials
4
Phase 3
6
Phase 2
1
Recruiting
118
Score

Pipeline by Phase

Phase 3
4
Phase 2
6
Phase 1

Therapeutic Focus

Achondroplasia Hypochondroplasia Advanced Cholangiocarcinoma FGFR2 Gene Mutation Upper Tract Urothelial Carcinomas

Clinical Trials (9)

NCT06164951 Phase 3 COMPLETED

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

Started: 11/10/2023

NCT03773302 Phase 3 TERMINATED

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Started: 12/27/2019

NCT04197986 Phase 3 TERMINATED

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Started: 3/11/2020

NCT07169279 Phase 2 RECRUITING

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

Started: 11/19/2025

NCT07393373 Phase 2 ENROLLING BY INVITATION

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

Started: 4/23/2026

NCT06873035 Phase 2 ENROLLING BY INVITATION

An Interventional Study of Infigratinib in Children With Hypochondroplasia

Started: 4/22/2025

NCT05145010 Phase 2 ENROLLING BY INVITATION

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Started: 12/6/2021

NCT04265651 Phase 2 COMPLETED

Study of Infigratinib in Children With Achondroplasia

Started: 3/10/2020

NCT02150967 Phase 2 TERMINATED

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Started: 7/23/2014

Drug Candidates

Infigratinib is provided as a single dose of minitablets for oral administration Infigratinib is provided as sprinkle capsules for daily oral administration Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration Infigratinib 0.25 mg/kg/day Infigratinib infigratinib 0.128 mg/kg/day infigratinib 0.25 mg/kg/day Infigratinib 0.016 mg/kg Infigratinib 0.032 mg/kg Infigratinib 0.064 mg/kg
Activity Status: Active
Last Trial Started: 4/23/2026
Last Trial Ended: 12/18/2025
Trials (12 months): 2
Completed Trials: 2
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.